These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17525656)

  • 1. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
    Mah FS; Romanowski EG; Kowalski RP; Yates KA; Gordon YJ
    Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
    Romanowski EG; Mah FS; Yates KA; Kowalski RP; Gordon YJ
    Am J Ophthalmol; 2005 May; 139(5):867-77. PubMed ID: 15860293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
    Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
    Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
    Jensen H; Zerouala C; Carrier M; Short B
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
    Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
    Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of experimental bacterial keratitis with topical trovafloxacin.
    Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
    Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
    Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
    Kowalski RP; Romanowski EG; Mah FS; Shanks RM; Gordon YJ
    Acta Ophthalmol; 2010 Jun; 88(4):e120-5. PubMed ID: 20456251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
    Balzli CL; McCormick CC; Caballero AR; Huang B; Wigington L; Smith E; Tang A; O'Callaghan RJ
    J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
    Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
    Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
    Karicherla P; Hobden JA
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):256-62. PubMed ID: 18775859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
    Guzek JP; Chacko D; Kettering JD; Wessels IF; Aprecio RM
    Cornea; 1994 Nov; 13(6):500-4. PubMed ID: 7842708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
    Sarayba MA; Shamie N; Reiser BJ; Sweet PM; Taban M; Graff JM; Kesler-Diaz A; Osann KE; McDonnell PJ
    J Cataract Refract Surg; 2005 Jul; 31(7):1396-402. PubMed ID: 16105613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mupirocin and polymyxin B in experimental Staphylococcus aureus, Pseudomonas aeruginosa, and Serratia marcescens keratitis.
    Moreau JM; Conerly LL; Hume EB; Dajcs JJ; Girgis DO; Cannon BM; Thibodeaux BA; Stroman DW; O'Callaghan RJ
    Cornea; 2002 Nov; 21(8):807-11. PubMed ID: 12410042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
    Hyon JY; Joo MJ; Hose S; Sinha D; Dick JD; O'Brien TP
    Arch Ophthalmol; 2004 Aug; 122(8):1166-9. PubMed ID: 15302657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keratotomy model of pseudomonas keratitis: gentamicin chemotherapy.
    Brockman EB; Tarantino PA; Hobden JA; Hill JM; O'Callaghan RJ; Kaufman HE; Insler MS
    Refract Corneal Surg; 1992; 8(1):39-43. PubMed ID: 1554638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
    Lauffenburger MD; Cohen KL
    Cornea; 1993 Nov; 12(6):517-21. PubMed ID: 8261784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
    Parmar P; Salman A; Kalavathy CM; Kaliamurthy J; Prasanth DA; Thomas PA; Jesudasan CA
    Am J Ophthalmol; 2006 Feb; 141(2):282-286. PubMed ID: 16458681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.